title: Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
authors.affiliation: Azienda Ospedaliera Treviglio, UO Oncologia Medica, Treviglio, BG, Italia. Electronic address: faupe@libero.it.
authors.forename: Fausto
authors.initials: F
authors.lastname: Petrelli
authors.affiliation: Azienda Ospedaliera Treviglio, UO Oncologia Medica, Treviglio, BG, Italia.
authors.forename: Sandro
authors.initials: S
authors.lastname: Barni
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D017697:Premenopause; D011960:Receptors, Estrogen / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D011960:Receptors, Estrogen; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone